IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Role Of Nutraceuticals In Preventing And Managing Life Style Disorders

Author's Name: Vansh maurya*, Ritik soni*,Vishal kannaujiya* Budhiman*, Suraj kannaujiya
Nirmala Devi Pharmacy College, jaunpur

Abstract

The current healthcare landscape is moving from treating illnesses to focusing on overall wellness, with nutraceuticals playing an important role. Nutraceuticals are bioactive compounds in food that offer health benefits beyond basic nutrition. This review summarizes the latest evidence on how nutraceuticals address common lifestyle-related issues, including metabolic problems, heart diseases, joint degeneration, cognitive decline, and gut issues. We evaluate the scientific basis, laboratory studies, and human clinical trials for major categories of nutraceuticals: omega-3 fatty acids for heart health and reducing inflammation; dietary fibers that influence metabolism and blood sugar; polyphenols like curcumin and resveratrol that help manage inflammation and oxidative stress; glucosamine and chondroitin for supporting joint cartilage; probiotics that restore the balance of gut microbiomes; and adaptogenic herbs that boost resilience to stress. We also discuss challenges like the absorption of these compounds, the need for consistent quality, potential interactions with medications, and varying regulatory standards. The evidence shows that many nutraceuticals can deliver real benefits when properly tested. However, using them effectively requires professional guidance, strict quality control, and incorporation into wider lifestyle changes. Future research might focus on personalized nutrition based on genetics and targeted treatments for gut health.

Keywords: Nutraceuticals, Functional Foods, Metabolic Syndrome, Omega-3 Fatty Acids, Curcumin, Probiotics, Chronic Disease Prevention, Phytochemicals.

INTRODUCTION

Any food-derived substance that offers health or medical benefits, such as disease prevention and therapeutic management, is included in the conceptual framework of nutraceuticals, which was first presented by DeFelice in 1989. Nutraceuticals are naturally occurring bioactive compounds that are extracted from whole foods or prepared as concentrated dietary supplements, in contrast to conventional pharmaceutical agents, which are synthetic molecular entities intended for particular pathophysiological targets. This differentiation places nutraceuticals in a distinct clinical and regulatory niche, connecting pharmacological intervention and nutritional science. According to recent epidemiological analyses, non-communicable chronic diseases account for roughly 71% of the world's mortality burden, and unless effective preventive measures are implemented, the burden is expected to continue rising. Despite their generally non-acute presentations, lifestyle-mediated conditions such as type 2 diabetes mellitus, essential hypertension, atherogenic dyslipidemia, obesity, osteoarthritis, anxiety spectrum disorders, and functional gastrointestinal disturbances are also referred to as "daily life disorders" due to their high prevalence and significant impact on quality of life. Genetic susceptibility, environmental exposures, prolonged oxidative stress, chronic subclinical inflammation, and progressive metabolic abnormalities all interact intricately in the multifactorial pathogenesis of these conditions.The current narrative review highlights both therapeutic

potential and enduring translational challenges while methodically synthesizing current mechanistic understanding and clinical evidence supporting major nutraceutical interventions across prevalent disorders of daily life.

NUTRACEUTICAL CLASSIFICATION AND FUNCTIONAL CHARECTORIZATION

Several complementary frameworks can be used to systematically classify nutraceuticals according to their primary biological functions, chemical makeup, and place of origin. Considering the source

- **PLANT-DERIVED NUTRACEUTICALS:**

This broad category includes alkaloids (caffeine, berberine), terpenoids carotenoids, such as lutein and lycopene, polyphenolic compounds (flavonoids, stilbenes, and curcuminoids), and organosulfur compounds (allicin from Allium species) .These phytochemicals typically exhibit pleiotropic biological activities targeting multiple physiological pathways.

- **NUTRACEUTICALS DERIVED FROM ANIMALS:**

Glucosamine from crustacean exoskeletons, conjugated linoleic acid, bioactive collagen peptides, and omega-3 polyunsaturated fatty acids from marine organisms are the most common examples . In mammalian physiology, these substances usually have structural or signaling functions.

- **MICROBIAL-DERIVED NUTRACEUTICALS:**

Live probiotic microorganisms, particularly Lactobacillus and Bifidobacterium genera, alongside their metabolic products (postbiotics) and fungal-derived beta-glucans constitute this category . Their primary mechanisms involve microbiome modulation and immunological regulation.

MECHANISM-BASED FUNCTIONAL CATEGORIZATION:-

- **ANTIOXIDANT AGENTS:**

Reactive oxygen species neutralization and oxidative stress attenuation are the main ways that substances such as vitamins C and E, polyphenols, and carotenoids work.

- **ANTI-INFLAMMATORY MODULATORS:**

By inhibiting the inflammatory cascade through cyclooxygenase, lipoxygenase, and nuclear factor-kappa B pathway interference, omega-3 fatty acids, curcumin, and boswellic acids primarily produce therapeutic effects.

- **METABOLIC REGULATORS:**

Alpha-lipoic acid, chromium, and berberine exhibit primary activity via cellular energy sensing pathways, specifically through the enhancement of insulin signaling and AMP-activated protein kinase activation.

1. NUTRACEUTICAL IN THE MANAGEMENT OF METABOLIC SYNDROME

The metabolic syndrome is a collection of interrelated cardiometabolic risk factors that increase the risk of cardiovascular disease and type 2 diabetes. These factors include insulin resistance, central adiposity, atherogenic dyslipidaemia, which is characterised by elevated triglycerides and decreased HDL cholesterol, and elevated blood pressure.

- **POLYUNSATURATED FATTY ACIDS OMEGA-3**

The long-chain omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are primarily obtained from cold-water marine fish and microalgae, exhibit a variety of metabolic advantages. Mechanistically, these fatty acids function as biosynthetic precursors for specific pro-resolving mediators, such as protectins, maresins, and resolvens, which actively stop inflammatory reactions instead of just inhibiting their onset. Furthermore, EPA and DHA modulate transcriptional programs that control lipid metabolism by acting as endogenous ligands for peroxisome proliferator-activated receptors. Pharmaceutical-grade icosapent ethyl (highly purified EPA) administered at a dose of 4 grams per day resulted in a 25% relative risk reduction in major adverse cardiovascular events among statin-treated patients with residual hypertriglyceridemia, according to the historic reduce it cardiovascular outcomes trial .

Omega-3 supplementation at 2-4 grammes per day consistently lowers serum triglyceride concentrations by 15-30%, with minimal effects on low-density lipoprotein cholesterol and modest increases in high-density lipoprotein cholesterol, according to systematic meta-analyses involving multiple randomised controlled trials. Evidence synthesis suggests modest but statistically significant improvements in insulin sensitivity indices with respect to glycaemic regulation, especially in populations with established metabolic dysfunction

- **GLYCAEMIC CONTROL AND DIETARY FIBRES**

Dietary fibre is functionally classified as either soluble (viscous, easily fermentable) or insoluble (non-viscous, minimally fermentable) forms, representing indigestible plant food components. In the gastrointestinal lumen, soluble fibres such as pectin, psyllium husk, oat and barley beta-glucans, and inulin-type fructans create viscous aqueous gels that slow down the kinetics of nutrient absorption and gastric emptying. Soluble fibre binds intestinal bile acids, preventing enterohepatic recirculation and requiring de novo hepatic bile acid synthesis from cholesterol. This lowers circulating cholesterol pools .According to approved health claims from the European Food Safety Authority, consuming 3 grams of beta-glucan per day from barley or oat sources can lower blood cholesterol levels.Concerning glycemic control, soluble fiber consumption blunts postprandial glucose excursions by retarding carbohydrate enzymatic digestion and absorption, thereby improving overall glycemic regulation in type 2 diabetes.

Colonic bacterial fermentation of soluble fibers generates short-chain fatty acidsprincipally acetate, propionate, and butyratethat exert favorable metabolic effects including satiety enhancement via enteroendocrine cell stimulation of glucagon-like peptide-1 and peptide YY secretion, insulin sensitivity improvement, and anti-inflammatory signaling through G-protein coupled receptor activation.

- **BERBERINE AS A MODULATOR OF METABOLISM**

As a lipid-modulating and glucose-lowering nutraceutical, berberine, an isoquinoline alkaloid phytochemical that is extracted from a variety of Berberis species, has attracted a lot of research interest. The main mechanism is AMP-activated protein kinase activation, a master cellular energy status sensor that increases the uptake of glucose by skeletal muscle, inhibits the production of hepatic gluconeogenesis, and stimulates the oxidation of fatty acids. Berberine administration at 0.9-1.5 grammes daily decreased fasting plasma glucose by about 15.5 mg/dL and glycated haemoglobin by 0.71 percentage points, according to a thorough meta-analysis that synthesised 14 randomised controlled trials with 1,068 participants with type 2 diabetes. This showed efficacy comparable to first-line pharmaceutical agents.

Additional advantages include a slight decrease in body weight and a decrease in low-density lipoprotein cholesterol. However, there is a moderate frequency of gastrointestinal side effects, such as diarrhoea and constipation, and significant quality variation among commercial preparations calls for cautious product selection

2. OPTIMISATION OF CARDIOVASCULAR HEALTH

- **CONTROL OF BLOOD PRESSURE**

Increased endothelial nitric oxide synthase expression, increased nitric oxide bioavailability that promotes vasodilation, decreased vascular smooth muscle contractility, and anti-inflammatory effects on arterial walls are some of the complementary mechanisms by which omega-3 polyunsaturated fatty acids exhibit antihypertensive properties in addition to their triglyceride-lowering effects. Combined EPA and DHA supplementation at doses greater than 3 grammes daily decreased systolic blood pressure by 4.51 mm Hg and diastolic blood pressure by 3.05 mm Hg, with more noticeable effects seen in untreated hypertensive populations, according to a dose-response meta-analysis that included 70 randomised trials.

Coenzyme Q10, a strong lipophilic antioxidant and vital component of the mitochondrial electron transport chain, exhibits cardiovascular protective qualities. CoQ10 supplementation at 100300 mg daily decreased systolic blood pressure by 11 mm Hg and diastolic blood pressure by 7 mm Hg in hypertensive individuals, according to a systematic review and meta-analysis of 17 randomised controlled trials . Other cardiovascular benefits include reduced oxidative stress biomarkers, enhanced endothelial function, and possible benefits in the treatment of chronic heart failure. Rich in organosulfur compounds, especially S-allyl cysteine from allicin transformation, aged garlic extract has the ability to lower blood pressure. Meta-analytic evidence from controlled trials indicates that aged garlic extract at 600-2,400 mg daily reduces systolic blood pressure by 8-10 mm Hg in hypertensive subjects through mechanisms involving endothelial nitric oxide production stimulation and angiotensin-converting enzyme inhibition.

3. OSTEOARTHRITIS AND MUSCULOSKELETAL HEALTH

Over 300 million people worldwide suffer from osteoarthritis, a progressive degenerative joint disease that is typified by subchondral bone remodelling, articular cartilage degradation, and chronic pain symptoms.

- **NUTRACEUTICALS THAT SUPPORT CARTILAGE**

Endogenous cartilage extracellular matrix components include chondroitin sulphate, a sulfated glycosaminoglycan, and glucosamine, an amino monosaccharide. According to the therapeutic hypothesis, exogenous supplementation has mild anti-inflammatory effects and supplies biosynthetic substrates for the synthesis of proteoglycans. Although later meta-analyses show inconsistent results, the seminal Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT) found that combined supplementation offered moderate pain relief in subgroups with moderate-to-severe knee osteoarthritis. Given their good safety profiles and modest symptomatic benefits, current clinical practice guidelines conditionally recommend glucosamine sulphate at 1,500 mg daily and chondroitin at 1,200 mg daily.

- **BOTANICAL INTERVENTIONS TO REDUCE INFLAMMATION**

The main curcuminoid found in turmeric (Curcuma longa), curcumin, is a pleiotropic anti-inflammatory agent that inhibits a variety of molecular targets, such as pro-inflammatory cytokines (tumour necrosis factor-alpha, interleukin-1 beta, and interleukin-6), nuclear factor-kappa B, cyclooxygenase-2, and 5-lipoxygenase. A systematic review synthesizing nine randomized controlled trials encompassing 1,135 participants determined that curcumin extracts at 1,000-1,500 mg daily (frequently co-administered with piperine for bioavailability enhancement) significantly reduced pain scores and improved physical function, with efficacy comparable to non-steroidal anti-inflammatory drugs but superior gastrointestinal tolerability.

As strong 5-lipoxygenase inhibitors, boswellic acidsin particular, acetyl-11-keto-beta-boswellic acid, which is extracted from Boswellia serrata resinsuppress the biosynthesis of leukotrienes, which are important

pro-inflammatory lipid mediators. Within 48 weeks of consistent administration, clinical studies using standardised Boswellia extracts at 100-250 mg acetyl-11-keto-beta-boswellic acid daily show a significant reduction in osteoarthritis pain and an improvement in function.

4. COGNITIVE FUNCTION AND MENTAL WELL-BEING

- **Memory Enhancement and Neuroprotection**

Neuronal membrane fluidity, neurogenesis, and synaptic plasticity all depend on docosahexaenoic acid (DHA), an omega-3 fatty acid that makes up about 40% of neuronal membrane phospholipids. Increased dietary DHA intake is linked to a lower risk of Alzheimer's disease, according to epidemiological studies. Interventions in mild cognitive impairment and cognitively healthy older adults show improvements in memory and executive function, especially when baseline omega-3 nutritional status is suboptimal, while supplementation trials in established dementia show limited efficacy.

Bacosides, triterpenoid saponins found in the traditional Ayurvedic plant Bacopa monnieri (Brahmi), improve synaptic neurotransmission by modulating cholinergic, serotonergic, and dopaminergic pathways and offer antioxidant neuroprotection. Meta-analyses show that in healthy adults and older populations, chronic administration of 300-450 mg daily standardised extract for at least 12 weeks significantly improves memory acquisition, consolidation, and retrieval.

5. ANXIOLYTIC EFFECTS AND STRESS RESILIENCE

By modulating the hypothalamic-pituitary-adrenal axis and sympathoadrenal system, adaptogens are botanical compounds that increase non-specific resistance to stressors . Active withanolides found in Withania somnifera (ashwagandha) have GABA ergic activity, attenuate cortisol secretion, and modulate stress-responsive neurotransmitters. Ashwagandha root extract at 300-600 mg daily (standardised to at least 5% withanolides) significantly decreased anxiety symptom scores and serum cortisol concentrations, according to a meta-analysis of five randomised controlled trials with 400 participants .

Rhodiola rosea, which contains salidroside and bioactive rosavins, improves mood parameters, lessens burnout symptoms, and improves mental performance during fatigue states. Improvements in mental fatigue, sustained attention, and stress-induced cognitive errors have been shown in controlled trials using 200-600 mg daily.

6. MICROBIOME MODULATION AND GASTROINTESTINAL HEALTH

The composition of the gut microbiota has a direct impact on the gastrointestinal (GI) system, which is essential for digestion, immunity, and metabolic regulation.Probiotics like Lactobacillus and Bifidobacterium species aid in the restoration of good bacteria, the fortification of the intestinal barrier, the reduction of inflammation, and the enhancement of the production of short-chain fatty acids (SCFAs), especially butyrate, which promotes metabolic health. Prebiotics that specifically encourage the growth of these advantageous microorganisms and enhance intestinal function include inulin, fructo-oligosaccharides (FOS), and galacto-oligosaccharides (GOS). Green tea extract, curcumin, and resveratrol are examples of polyphenol-rich nutraceuticals that modulate the gut microbial community to produce effects similar to those of prebiotics.A number of herbs that have long been used to promote digestive health also help to modulate the microbiome. Aloe vera, peppermint, ginger, and liquorice (Glycyrrhiza glabra) all have antibacterial and anti-inflammatory qualities and enhance motility and lessen dyspepsia. These herbs and nutraceuticals work together to improve metabolic outcomes, lower endotoxemia, and restore gut homeostasis, making them useful supplements in the management and prevention of lifestyle disorders.

TABLE: MAJOR NUTRACEUTICALS FOR LIFESTYLE DISORDERS

NUTRACEUTICAL	PRIMARLY TARGET DISORDER	KEY MECHANISM	EFFECTIVE DOSE
Omega-3 (EPA/DHA)	Hyperglysemia,Hypertension, Inflammation	↓Triglyceride synthesis,Specialized Pro-resolving Mediators production, ↑Nitricoxide	2-4 g/day
Soluble Fiber (Beta-glucan)	Hypercholestrolemia, Dysglysemia	Bile acid binding, ↓Glucose absorption, Short chain fatty acid production	3 g/day
Berberine	Type 2 Diabetes, Dyslipidemia	AMP-activated Protienkinase activation, ↑Glucose uptake	0.9-1.5 g/day
Curcumin	Osteoarthritis, Inflammation	Nuclear Factor kappa-light-chain-enhancer of activated B cells ,Cyclooxygenase-2 Inhibition	1-1.5 g/day (with piperine)
Ashwagandha	Stress, Anxiety	Hypothalmic-Pitutary-Adrenal Modulation, ↓Cortisol	300-600 mg/day
Co-enzyme Q10	Hypertension, Heart failure	Mitochondrial energetics, Antioxidant	100-300 mg/day
Garlic extract	Hypertension, Dyslipidemia	↑Nitricoxide, Angiotensin converting Enzyme Inhibition	600-2400 mg/day
Glucosamine Chondriotin	Osteoarthritis	Cartilage substrate, Mild Anti-inflamatory	1200-1500 mg/day
Probiotic (Multi strain)	Irritating Bowl Syndrome, Gut Dysbiosis , Antibiotic Associated Diarrhea	Microbiome resrtoration, Immune Modulation	10^9-10^{10} CFU/day
Bocopa Minnieri extract	Memmory,Cognition	Cholenergic Modulation, Antioxidant	300-450 mg/day

HERB-DRUG INTERACTIONS AND SAFETY ASPECTS

Certain nutraceuticals raise safety concerns and possible drug interactions that require clinical awareness, even though they are generally thought to be safe at recommended dosages.

Interactions of Clinical Significance

The hepatic cytochrome P450 3A4 and intestinal P-glycoprotein efflux transporter are strongly induced by the botanical antidepressant, which lowers the plasma concentrations and therapeutic effectiveness of many drugs, such as warfarin, cyclosporine, tacrolimus, oral contraceptives, and protease inhibitors. T -chain-enhancer of activated B cells ,Cyclooxygenase-2 Inhibition

Ginkgo biloba: Antiplatelet and anticoagulant properties may potentiate bleeding risk when combined with warfarin, clopidogrel, or aspirin, necessitating coagulation parameter monitoring and possible discontinuation prior to surgical procedures.

Omega-3 Fatty Acids and Garlic: Both demonstrate antiplatelet effects through thromboxane synthesis inhibition, potentially augmenting bleeding risk when combined with anticoagulant or antiplatelet medications, though clinical significance remains debated.

Berberine: Through additive glucose-lowering effects, it may intensify hypoglycemic pharmaceutical agents, requiring blood glucose monitoring and potential dose adjustments for medications.

FUTURE GOALS AND NEW PARADIGMS

- **PERSONALISED NUTRITION AND NUTRIGENOMICS**

Understanding that genetic polymorphisms significantly impact individual nutraceutical responses, nutrigenomics studies the interactions between genes and nutrients. For example, compared to non-carriers, carriers of the apolipoprotein E epsilon-4 allele show different reactions to omega-3 supplementation for cognitive outcomes. Genotype-guided nutraceutical recommendations that maximize therapeutic efficacy while reducing side effects may be incorporated into future applications.

- **PROBIOTICS AND POSTBIOTICS OF THE NEXT GENERATION**

Next-generation probiotic candidates that are presently undergoing clinical research include emerging beneficial bacterial strains like Faecalibacterium prausnitzii, which produces anti-inflammatory metabolites, and Akkermansia muciniphila, which improves metabolic health by optimizing the mucin layer. While retaining biological activity, postbioticsnon-viable bacterial components and metabolites such as bacteriocins and short-chain fatty acidsoffer stability advantages over live probiotics .

CONCLUSION

Nutraceuticals represent a scientifically substantiated, increasingly evidence-based approach to chronic disease prevention and adjunctive management. The bioactive compounds reviewedomega-3 polyunsaturated fatty acids, dietary fibers, curcumin, probiotics, berberine, and adaptogensdemonstrate mechanistic plausibility and clinical efficacy across metabolic, cardiovascular, musculoskeletal, cognitive, and gastrointestinal health domains. However, successful translation from research evidence to clinical outcomes demands rigorous attention to formulation science, bioavailability optimization, quality assurance protocols, and individualized application. Nutraceuticals should be conceptualized not as pharmaceutical replacements or alternatives to evidence-based lifestyle modifications, but rather as valuable adjunctive interventions within comprehensive, integrative wellness strategies. As the field advances through sophisticated delivery technologies, nutrigenomic insights, and microbiome science, the therapeutic potential of food-derived bioactive compounds will be increasingly realized, contributing substantively to global preventive health initiatives.

REFERENCES:

1. Chintale Ashwini G, Kadam Vaishali S, Sakhare Ram S, Birajdar Ganesh O, Nalwad Digambar N.Role of nutraceuticals in various diseases: A comprehensive review. Int J Res Pharm Chem. 2013;3:2909.

2. Sosnowska B, Penson P, Banach M. The role of nutraceuticals in the prevention of cardiovascular Disease. Cardiovascular diagnosis and therapy. 2017;7(Suppl 1):S21.

3. Venkateswaran S, Pari L. Effect of Coccinia indica leaves on antioxidant status in Streptozotocininduced diabetic rats. J Ethnopharmacol, 2003; 84(2- 3): 163168.

4. Das L. Bhaumik, E. Raychaudhuri, U., and Chakraborty, R. Role of nutraceuticals in human health Journal of Food Science and Technology, 2012; 49: 173183.

5. Wang Z. Liu H. W. Regeneration of skeletal system with genipin crosslinked biomaterials. J Tissue Eng. 11:2041731420974861. doi:10.1177/ 204 1731420974861.6, 2020.

6. Castro F. and Souza HD. Dietary Composition and Effects in Inflammatory Bowel Disease.Nutrients, 2019; 11(6): 1398. doi:10.3390/nu11061398.8.

7. Kuijpers MC. Dijkstra G. Food and Food Groups in Inflammatory Bowel Disease (IBD): TheDesign of the Groningen Anti-Inflammatory Diet (GrAID), 2021; 13(4): 1067.Doi:10.3390/nu13041067.9.

8. Tan BL. Norhaizan ME. Liew WP. And Rahman S. Antioxidant and Oxidative Stress: A MutualInterplay in Age-Related Diseases. Front Pharmacol, 2018; 9: 1162. doi:10.3389/fphar.2018.01162.10.

9. Sarella PN, Dadishetti JP, Asogwa PO, Kakarparthy R. Pharmacological and Non-pharmacologicalManagement of Bipolar Disorder with Comorbid Huntington's Disease: A Case Report. Journal ofClinical and Pharmaceutical Research. 2023 Apr 30:5-8.

10. Bhatt DL, et al. Cardiovascular risk reduc- tion with icosapent ethyl. N Engl J Med. 2019;380(1):1122

11. EFSA Panel. Scientific opinion on beta-glucans. EFSA J. 2011;9(6):2207.

12. Lan J, et al. Berberine in type 2 diabetes: meta- analysis. J Ethnopharmacol. 2015;161:6981.

13. Daily JW, et al. Turmeric extracts for joint arthri- tis. J Med Food. 2016;19(8):71729

14. Ford AC, et al. Probiotics in IBS: meta-analysis. Am J Gastroenterol. 2014;109(10):154761.

15. Clegg DO, et al. Glucosamine, chondroitin for knee OA. N Engl J Med. 2006;354(8):795808.

16. Pratte MA, et al. Ashwagandha for anxiety. J Al- tern Complement Med. 2014;20(12):901-8.

17. Kongkeaw C, et al. Bacopa: meta-analysis on cognitive effects. J Ethnopharmacol. 2014;151(1):52835.

18. Ried K, et al. Aged garlic extract reduces blood pressure. Eur J Clin Nutr. 2013;67(1):6470.

19. Rosenfeldt FL, et al. CoQ10 in hypertension: meta-analysis. J Hum Hypertens. 2007;21(4):297 306.

20. Park C, Baek Y. Between Medicines and Nutraceuticals in the Control of Diabetes Mellitus. AsianJournal of Pharmaceutical Research and Development. 2024;12(2):138.

21. DeFelice SL. The nutraceutical revolution: its impact on food industry research and development. Trends Food Sci Technol. 1995;6(2):59-61.

22. Kalra EK. Nutraceuticaldefinition and introduction. AAPS PharmSci. 2003;5(3):E25. doi:10.1208/ps050325

23. World Health Organization. Noncommunicable diseases country profiles 2018. Geneva: WHO; 2018.

24. Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1736-1788.

25. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-1832.

26. Grand View Research. Nutraceuticals market size, share & trends analysis report by product, by application, by region, and segment forecasts, 2023-2030. Market Analysis Report, 2023.

27. Santini A, Tenore GC, Novellino E. Nutraceuticals: a paradigm of proactive medicine. Eur J Pharm Sci. 2017;96:53-61.

28. Manach C, Scalbert A, Morand C, Remesy C, Jimenez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004;79(5):727-747.

29. Calder PC. Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance. Biochim Biophys Acta. 2015;1851(4):469-484.

30. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514.

31. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010;4(8):118-126.

32. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol. 2013;75(3):645-662.

33. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262.

34. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491-502.

35. Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12.

36. Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest. 2018;128(7):2657-2669.

37. Jump DB, Depner CM, Tripathy S. Omega-3 fatty acid supplementation and cardiovascular disease. J Lipid Res. 2012;53(12):2525-2545.

38. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.

39. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):e673-e691.

40. Akinkuolie AO, Ngwa JS, Meigs JB, Djousse L. Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials. Clin Nutr. 2011;30(6):702-707.

41. Slavin JL. Position of the American Dietetic Association: health implications of dietary fiber. J Am Diet Assoc. 2008;108(10):1716-1731.

42. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69(1):30-42.

43. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on the substantiation of health claims related to beta-glucans from oats and barley. EFSA J. 2011;9(6):2207.

44. Post RE, Mainous AG 3rd, King DE, Simpson KN. Dietary fiber for the treatment of type 2 diabetes mellitus: a meta-analysis. J Am Board Fam Med. 2012;25(1):16-23.

45. Koh A, De Vadder F, Kovatcheva-Datchary P, Baeckhed F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell. 2016;165(6):1332-1345.

46. Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256-2264.

47. Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81.

48. Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): a clinical review. Phytother Res. 2019;33(3):504-523.